Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ketoprofen
Drug ID BADD_D01231
Description Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Indications and Usage For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Marketing Status approved; vet_approved
ATC Code M01AE03; M02AA10
DrugBank ID DB01009
KEGG ID D00132
MeSH ID D007660
PubChem ID 3825
TTD Drug ID D0W9WF
NDC Product Code 51604-0011; 71574-122; 0276-0506; 43235-0010; 51927-0304; 76465-0001; 12660-0006; 38779-3039; 49452-3924; 51927-0231; 45865-485; 0276-0504; 51927-0025; 51927-0057; 68981-031; 63275-9996; 82348-102; 63187-018; 38779-0078; 0378-8200; 51552-0307; 51927-0299; 79572-019
UNII 90Y4QC304K
Synonyms Ketoprofen | Benzoylhydratropic Acid | 2-(3-Benzoylphenyl)propionic Acid | Profenid | Alrheumum | Orudis | 19,583 RP | RP, 19,583 | RP-19583 | RP 19583 | RP19583 | Alrheumat
Chemical Information
Molecular Formula C16H14O3
CAS Registry Number 22071-15-4
SMILES CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.0020.008961%
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.0110.002240%Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.0420.002240%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.003361%Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intentional self-injury19.12.01.002; 12.01.08.0360.002240%Not Available
Intestinal ulcer07.04.06.003--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.006049%Not Available
Lactic acidosis14.01.01.0020.002240%Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.002240%
Linear IgA disease23.03.01.015; 10.04.02.0060.006721%Not Available
Lip oedema07.05.04.004; 23.04.01.006; 10.01.05.0040.011202%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.002240%Not Available
Loss of consciousness17.02.04.0040.005601%Not Available
Lung disorder22.02.07.0010.005601%Not Available
Malaise08.01.01.003--
Melaena24.07.02.013; 07.12.02.0040.014562%Not Available
Meningitis aseptic17.06.03.002; 11.01.03.002--Not Available
Menometrorrhagia21.01.03.001--Not Available
Metabolic acidosis14.01.01.0030.005601%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis17.02.11.002; 06.05.03.0030.008961%Not Available
Mouth ulceration07.05.06.004--Not Available
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myoclonus17.02.05.0080.002240%Not Available
Myositis15.05.01.0010.002240%
Nasal obstruction22.12.03.0130.002240%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene